Prognostic Implication of Negative Lymph Node Count in ypN+ Rectal Cancer after Neoadjuvant Chemoradiotherapy and Construction of a Prediction Nomogram
This study aimed to investigate the prognostic significance of negative lymph nodes (NLNs) for ypN+ rectal cancer after neoadjuvant chemoradiotherapy (nCRT) and radical surgery and to construct a nomogram predicting disease-free survival (DFS).
One hundred fifty-eight eligible patients were included. X-tile analysis was performed to determine cutoff values of NLNs. Clinicopathological and survival outcomes were compared. A Cox regression analysis was performed to identify prognostic factors of DFS. A nomogram was constructed and validated internally.
X-tile analysis identified cutoff values of 4 and 16 in terms of DFS (χ2 = 8.129, p = 0.017). The 3-year DFS rates for low (≤ 4), middle (5–16), and high (≥ 17) NLNs group was 15.2, 55.5, and 73.1%, respectively (P = 0.017). NLN count (NLNs ≥ 17, HR = 0.400, P = 0.022), IMA nodal metastasis (HR = 1.944, P = 0.025), tumor differentiation (poor/anaplastic, HR = 1.805, P = 0.021), and ypT4 stage (HR = 7.787, P = 0.047) were independent prognostic factors of DFS. A predicting nomogram incorporating the four significant predictors was developed with a C-index of 0.64.
NLN count was an independent prognostic factor of DFS in patients with ypN+ rectal cancer following nCRT. A nomogram incorporating NLN count, IMA nodal metastasis, tumor differentiation, and ypT stage could stratify rectal cancer patients with different DFS and might be helpful during clinical decision-making.
KeywordsRectal cancer Chemoradiotherapy Negative lymph nodes Prognosis Nomogram
This study was supported by National Clinical Key Specialty Construction Project (General Surgery) of China (Grant number 2012-649), Startup Fund for scientific research, Fujian Medical University (Grant number 2017XQ1028), and guiding key project of social development by the Fujian Provincial Science and Technology Department (Grant number 2015Y0058).
Yanwu Sun and Pan Chi designed the study. Yanwu Sun, Yiyi Zhang, and Zhekun Huang collected the data and were major contributors in writing the manuscript. All the authors read and approved the final manuscript.
Compliance with Ethical Standards
This study was performed according to the ethical principles described in the Declaration of Helsinki. The institutional review board (IRB) of our hospital approved this study.
Conflict of Interest
The authors declare that they have no conflict of interest.
- 1.Roh MS, Colangelo LH, O'Connell MJ, Yothers G, Deutsch M, Allegra CJ, Kahlenberg MS, Baez-Diaz L, Ursiny CS, Petrelli NJ, Wolmark N. Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. J Clin Oncol. 2009; 27: 5124–30.CrossRefGoogle Scholar
- 2.van Gijn W, Marijnen CA, Nagtegaal ID, Kranenbarg EM, Putter H, Wiggers T, Rutten HJ, Pahlman L, Glimelius B, van de Velde CJ. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol. 2011; 12: 575–82.CrossRefGoogle Scholar
- 3.Sauer R, Liersch T, Merkel S, Fietkau R, Hohenberger W, Hess C, Becker H, Raab HR, Villanueva MT, Witzigmann H, Wittekind C, Beissbarth T, Rodel C. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol. 2012; 39: 1926–33.CrossRefGoogle Scholar
- 5.Schmoll H, Van Cutsem E, Stein A, Valentini V, Glimelius B, Haustermans K, Nordlinger B, van de Velde C, Balmana J, Regula J, Nagtegaal I, Beets-Tan R, Arnold D, Ciardiello F, Hoff P, Kerr D, Köhne C, Labianca R, Price T, Scheithauer W, Sobrero A, Tabernero J, Aderka D, Barroso S, Bodoky G, Douillard J, El Ghazaly H, Gallardo J, Garin A, Glynne-Jones R, Jordan K, Meshcheryakov A, Papamichail D, Pfeiffer P, Souglakos I, Turhal S, Cervantes A. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. Ann Oncol. 2012; 23: 2479–516.CrossRefGoogle Scholar
- 7.Okada K, Sadahiro S, Suzuki T, Tanaka A, Saito G, Kamijo A, Akiba T, Kawada S. Effects of chemoradiotherapy on lymph nodes in patients with rectal adenocarcinoma: evaluation of numbers and sizes of retrieved lymph nodes inside and outside the radiation field. Anticancer Res. 2014; 34: 4195–200.Google Scholar
- 8.Amin M, Edge S, Greene F, Byrd D, Brookland R, Washington M, Gershenwald J, Compton C, Hess K, Sullivan D, Jessup J, Brierley J, Gaspar L, Schilsky R, Balch C, Winchester D, Asare E, Madera M, Gress D, Meyer L, AJCC Cancer Staging Manual. 8th ed ed. 2017, New York: Springer. 252–74.CrossRefGoogle Scholar
- 11.Ogino S, Nosho K, Irahara N, Shima K, Baba Y, Kirkner G, Mino-Kenudson M, Giovannucci E, Meyerhardt J, Fuchs C. Negative lymph node count is associated with survival of colorectal cancer patients, independent of tumoral molecular alterations and lymphocytic reaction. Am J Gastroenterol. 2010; 105: 420–33.CrossRefGoogle Scholar
- 12.Wong J, Bowles B, Bueno R, Shimizu D. Impact of the number of negative nodes on disease-free survival in colorectal cancer patients. Dis Colon rectum. 2002; 45: 1341–8.Google Scholar
- 19.Habr-Gama A, Perez R, Proscurshim I, Rawet V, Pereira D, Sousa A, Kiss D, Cecconello I. Absence of lymph nodes in the resected specimen after radical surgery for distal rectal cancer and neoadjuvant chemoradiation therapy: what does it mean? Dis Colon rectum. 2008; 51: 277–83.Google Scholar
- 22.Beresford M, Glynne-Jones R, Richman P, Makris A, Mawdsley S, Stott D, Harrison M, Osborne M, Ashford R, Grainger J, Al-Jabbour J, Talbot I, Mitchell I, Meyrick Thomas J, Livingstone J, McCue J, MacDonald P, Northover J, Windsor A, Novell R, Wallace M, Harrison R. The reliability of lymph-node staging in rectal cancer after preoperative chemoradiotherapy. Clin Oncol (R Coll Radiol). 2005; 17: 448–55.CrossRefGoogle Scholar
- 28.Mogoantă S, Calotă F, Vasile I, Crafciuc A, Gherghinescu M, Sapalidis K, Ilie D, Ion D. Histological and immunohistochemical study on sentinel lymph node in colorectal cancer - values and limitations. Rom J Morphol Embryol. 2016; 57: 65–74.Google Scholar
- 29.Rahbari N, Bork U, Motschall E, Thorlund K, Büchler M, Koch M, Weitz J. Molecular detection of tumor cells in regional lymph nodes is associated with disease recurrence and poor survival in node-negative colorectal cancer: a systematic review and meta-analysis. J Clin Oncol. 2012; 30: 60–70.CrossRefGoogle Scholar
- 30.George S, Primrose J, Talbot R, Smith J, Mullee M, Bailey D, du Boulay C, Jordan H, Wessex Colorectal Cancer Audit Working G. Will Rogers revisited: prospective observational study of survival of 3592 patients with colorectal cancer according to number of nodes examined by pathologists. Br J Cancer. 2006; 95: 841–7.CrossRefGoogle Scholar
- 34.Ogino S, Nosho K, Irahara N, Shima K, Baba Y, Kirkner G, Mino-Kenudson M, Giovannucci E, Meyerhardt J, Fuchs C. Negative lymph node count is associated with survival of colorectal cancer patients, independent of tumoral molecular alterations and lymphocytic reaction. Am J Gastroenterol. 2010; 105: 420–33.CrossRefGoogle Scholar
- 40.Cui J, Yang L, Guo L, Shao Y, Tan D. The combination of early treatment response and ypT stage is a novel metric to stage rectal cancer patients treated with neoadjuvant chemoradiotherapy. Oncotarget. 2017; 8: 37845–54.Google Scholar
- 42.De Stefano A, Moretto R, Bucci L, Pepe S, Romano F, Cella A, Attademo L, Rosanova M, De Falco S, Fiore G, Raimondo L, De Placido S, Carlomagno C. Adjuvant treatment for locally advanced rectal cancer patients after preoperative chemoradiotherapy: when, and for whom? Clin Colorectal Cancer. 2014; 13: 185–91.CrossRefGoogle Scholar
- 43.Pita-Fernández S, Alhayek-Aí M, González-Martín C, López-Calviño B, Seoane-Pillado T, Pértega-Díaz S. Intensive follow-up strategies improve outcomes in nonmetastatic colorectal cancer patients after curative surgery: a systematic review and meta-analysis. Ann Oncol. 2015; 26: 644–56.CrossRefGoogle Scholar